Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD

INTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated safety and efficacy versus placebo in phase III trials in patients with anemia of chronic kidney disease (CKD) who were not on dialysis (NDD). METHODS: This was a phase III, active-control...

Descripción completa

Detalles Bibliográficos
Autores principales: Akizawa, Tadao, Iwasaki, Manabu, Otsuka, Tetsuro, Yamaguchi, Yusuke, Reusch, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258605/
https://www.ncbi.nlm.nih.gov/pubmed/34307976
http://dx.doi.org/10.1016/j.ekir.2021.04.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258605/
https://www.ncbi.nlm.nih.gov/pubmed/34307976
http://dx.doi.org/10.1016/j.ekir.2021.04.003

Ejemplares similares